Vapers and non-smokers have the same flourishing gut flora

 The first study of its kind has found that people who vape have the same mix of gut bacteria as non-smokers, whilst smokers have significant changes to their microbiome. The international team of researchers led by Newcastle University, analysed the bacteria of tobacco smokers, users of e-cigarettes and non-smokers from samples throughout the digestive tract, including in the mouth and ...

Read More »

Study identifies ways smaller hospitals can effectively reduce antibiotic overuse

Researchers at Intermountain Healthcare and University of Utah Health in Salt Lake City have completed a study identifying how community hospitals with fewer than 200 beds can develop antibiotic stewardship programs that work to prevent the growth of antibiotic-resistant organisms, or “superbugs,” which are becoming more common and deadly. For the 15 month-study, researchers compared the impact of three types ...

Read More »

Cheron Rojo Joins Healthmark Industries

Healthmark Industries is proud to announce Cheron Rojo, AA, CRCST, CIS, CER, CHL as the Clinical Education Coordinator – SPD.  “We are very pleased to welcome Cheron to Healthmark Industries,” says Vice President Ralph Basile. “His expert knowledge and experience in the SPD field will play a vital role in the development of our SPD product line and providing guidance ...

Read More »

Gut microbes influence severity of intestinal parasitic infections

A new study indicates that the kinds of microbes living in the gut influence the severity and recurrence of parasitic worm infections in developing countries. The findings, by researchers at Washington University School of Medicine in St. Louis, suggest that manipulating the gut’s microbial communities may protect against intestinal parasites, which affect more than 1 billion people worldwide. The study ...

Read More »

Gastrointestinal hormone measurably improved symptoms of non-alcoholic fatty liver disease

Through a randomized, double-blind, placebo-controlled phase II clinical trial, researchers at University of California San Diego School of Medicine report that small doses of NGM282, a non-tumorigenic variant of an endocrine gastrointestinal hormone, can significantly and rapidly decrease liver fat content in patients with non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The findings, they say, represent an important ...

Read More »